Altogether, these data from knockdown and rescued experiments strongly support the idea that the observed dysregulation in the metabolic profile was more likely fascin-dependent and not due to an off-target effect, and reveal a central role for fascin in modulating key metabolic pathways, which were reported to regulate the progression of various tumors, including breast cancer. This evidence concerns the gene FSCN1 and breast carcinoma.